Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals

Eugènia Negredo(Universitat de Vic - Universitat Central de Catalunya), Bonaventura Clotet(Universitat de Vic - Universitat Central de Catalunya), Jordi Puig(Universitat Autònoma de Barcelona), Peré Domingo(Hospital de Sant Pau), Anna Bonjoch(Universitat Autònoma de Barcelona), Carla Estany(Universitat Autònoma de Barcelona), María del Mar Gutiérrez(Evidence (Italy)), Patricia Echeverría(Universitat Autònoma de Barcelona), Gràcia Mateo(Evidence (Italy)), Arelly Ornelas(Universitat Autònoma de Barcelona), Jessica Toro(Universitat Autònoma de Barcelona), Vicente Estrada(Instituto de Salud Carlos III)
Journal of Antimicrobial Chemotherapy
November 2, 2016
10.1093/jac/dkw504
Cited by 11

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial
|The Lancet|2006|343